Kailera announced that its oral GLP-1 asset achieved 11% weight loss and met all goals in phase 3 clinical trials for obesity and diabetes conducted in China. The results were reported on July 7, 2026.
Kailera, a biopharmaceutical company, has reported positive results from its phase 3 clinical trials in China. The company’s oral GLP-1 receptor agonist led to an 11% reduction in body weight among study participants. The drug also met all of the predefined goals in the trials.
These outcomes cover two separate indications: obesity and type 2 diabetes. The trials were designed to evaluate the efficacy and safety of the oral GLP-1 asset in patients with these conditions. The 11% weight loss figure represents a significant measurement in obesity treatment.
The phase 3 trials were conducted entirely in China. Phase 3 is typically the final stage of clinical development before a company seeks regulatory approval. Kailera’s oral GLP-1 asset is part of a class of drugs that mimic the natural GLP-1 hormone, which helps regulate blood sugar levels and appetite.
An oral formulation offers potential advantages over injectable GLP-1 drugs, such as easier administration and improved patient compliance. The announcement came on July 7, 2026, and highlighted that the drug achieved its objectives in both the obesity and diabetes trials.
The 11% weight loss seen in the trials is a key metric for obesity treatments. For the diabetes portion, meeting the trial goals suggests the drug may help control blood glucose levels. Kailera has not provided further details on the specific endpoints or the safety profile, only stating that the goals were met.
These results position Kailera’s oral GLP-1 asset as a potential contender in the crowded GLP-1 market. The fact that the trials were completed in China adds geographic diversity to the data. The next steps for the program have not been disclosed in the announcement.
Kailera is the developer of this oral GLP-1 candidate. The company is focused on metabolic diseases, including obesity and diabetes. The asset is described as an oral GLP-1, meaning it is taken by mouth rather than injected. This could be a differentiating factor if the drug eventually reaches the market.
The trials addressed two major health conditions: obesity and type 2 diabetes. Both are areas of high unmet medical need, particularly in China where obesity rates have been rising. The positive phase 3 results are a milestone for Kailera’s pipeline.
Peptides referenced: GLP-1.
Related reading: Hengrui, Kailera GLP-1 Pill Shows Encouraging Efficacy but High Side Effects in China, Protagonist Therapeutics Provides Clinical Pipeline Update, Peptide therapy shows nerve repair in spinal cord injury clinical trial, Tampa General Hospital Sues Eli Lilly Over 340B Drug Discount Restrictions.